Literature DB >> 33146922

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.

Hong Zheng1, Shin Mineishi1, David Claxton1, Junjia Zhu2, Chenchen Zhao1, Bei Jia1, W Christopher Ehmann1, Witold B Rybka1, Seema Naik1, Natthapol Songdej1, Joseph J Drabick1, Raymond J Hohl1.   

Abstract

Entities:  

Keywords:  AML; PD-1; T cell exhaustion; avelumab; decitabine

Year:  2020        PMID： 33146922     DOI： 10.1002/ajh.26043

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis.

Authors:  Marina Gómez-Llobell; Andrés Peleteiro Raíndo; Jose Climent Medina; Ignacio Gómez Centurión; Adrián Mosquera Orgueira
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

Review 2.  Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.

Authors:  Yang Xu; Ping Li; Yang Liu; Dijia Xin; Wen Lei; Aibin Liang; Weidong Han; Wenbin Qian
Journal:  Cancer Commun (Lond)       Date:  2022-06-01

Review 3.  Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Yasmin Abaza; Amer M Zeidan
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

Review 4.  Targeted therapy in NPM1-mutated AML: Knowns and unknowns.

Authors:  Rong Wang; Pan Xu; Lin-Lin Chang; Shi-Zhong Zhang; Hong-Hu Zhu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 5.  Therapeutic Advances in Immunotherapies for Hematological Malignancies.

Authors:  Ayako Nogami; Koji Sasaki
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.